MAP's stock plummets as paediatric asthma drug fails Phase III
This article was originally published in Scrip
Executive Summary
MAP Pharmaceuticals and AstraZeneca's proprietary unit dose budesonide (UDB) for the treatment of asthma in children has failed to meet its primary endpoints in a Phase III trial.